Developer docs
API playgroundTry for free, no card

Search company profiles

Theravance Biopharma

Full company profile

uuid00033os

Namestring
Theravance Biopharma
Legal namestring
Theravance Biopharma US, LLC
Websiteurl
theravance.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Theravance Biopharma is a publicly traded biopharmaceutical company (NASDAQ: TBPH) headquartered in South San Francisco, California, with an additional office in Dublin, Ireland. The company was established in June 2014 as a spin-off from Innoviva and focuses on specialty respiratory diseases. Its commercial portfolio consists of a single FDA-approved product, YUPELRI (revefenacin) inhalation solution, a once-daily long-acting muscarinic antagonist (LAMA) delivered via nebulization for the maintenance treatment of chronic obstructive pulmonary disease (COPD). YUPELRI is co-commercialized in the United States through a strategic partnership with Viatris, under which Viatris handles sales force deployment, distribution, and managed markets while Theravance maintains brand leadership. The company also receives milestone payments from Royalty Pharma triggered by GSK-reported TRELEGY Ellipta net sales, with a $100 million payment expected in 2026.

Theravance's revenue model is structured around three streams: YUPELRI collaboration revenue shared with Viatris, sales-based milestones tied to YUPELRI performance ($75 million achieved in FY2025), and TRELEGY milestone payments from Royalty Pharma. FY2025 YUPELRI US net sales reached $266.6 million (up 12% year-over-year), with Q1 2026 collaboration revenue of $17.7 million (up 15% year-over-year). The company holds three US patents (11,484,531; 12,048,692; 12,285,417) on YUPELRI, and a March 2026 Hatch-Waxman settlement with Mankind Pharma extended generic-free exclusivity through April 2039.

Following the March 2026 failure of the Phase 3 CYPRESS trial for ampreloxetine (a norepinephrine reuptake inhibitor for neurogenic orthostatic hypotension), Theravance eliminated its R&D function and reduced its workforce by approximately 50%, from roughly 100 to 50 employees. The restructuring targets a 60% operating expense reduction and $60-70 million in annualized cash flow beginning in Q3 2026. The company holds approximately $400 million in cash with no debt as of Q1 2026, and a Strategic Review Committee, advised by Lazard, is actively evaluating potential sale of the company as a strategic alternative.

Short descriptiontext

Theravance Biopharma is a public biopharmaceutical company (NASDAQ: TBPH) that co-commercializes YUPELRI, a nebulized COPD maintenance therapy, with Viatris in the United States, and receives milestone payments from Royalty Pharma tied to GSK's TRELEGY sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
respiratory therapeutics, COPD treatment, inhaled pharmaceuticals, nebulized LAMA therapy, specialty biopharmaceuticals
Industry2 codes
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Respiratory Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1YUPELRI collaboration revenue
TypeLicensing Royalties
Description

Revenue from strategic collaboration with Viatris for co-commercialization of YUPELRI in the US. Viatris and Theravance co-commercialize the product, sharing economics.

in.investing.com
2TRELEGY milestone payments
TypeLicensing Royalties
Description

Royalty Pharma milestone payments triggered by GSK-reported TRELEGY net sales. $100 million milestone payment expected in 2026. Also received $50 million milestone payment previously.

stocktitan.net
3YUPELRI sales-based milestones
TypeLicensing Royalties
Description

Additional milestone payments tied to YUPELRI sales performance. $75 million in sales-based milestones achieved in FY2025.

finance.yahoo.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1YUPELRI (revefenacin)
Description

FDA-approved inhalation solution for maintenance treatment of COPD

theravance.com
+2 more records
Core offering1 text field

Theravance Biopharma is a specialty biopharmaceutical company that develops and commercializes therapeutics for respiratory diseases. Its core offering is YUPELRI® (revefenacin), an FDA-approved long-acting muscarinic antagonist (LAMA) inhalation solution for maintenance treatment of COPD, co-commercialized in the US with Viatris. The company also derives revenue from royalty milestone payments tied to GSK's TRELEGY Ellipta net sales through Royalty Pharma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • YUPELRI achieved $266.6M in FY2025 US net sales, up 12% year-over-year
+4 more records
Product overview1 text field

Theravance Biopharma is a biopharmaceutical company focused on respiratory, inflammatory, and rare diseases. The company's portfolio consists of one FDA-approved product (YUPELRI® for COPD) and one discontinued pipeline candidate (amprexloxetine for neurogenic orthostatic hypotension, terminated after Phase 3 failure). Following the March 2026 strategic restructuring after the ampreloxetine trial failure, the company eliminated its R&D function and is now focused solely on commercializing YUPELRI in partnership with Viatris, while receiving milestone payments from GSK's TRELEGY (though the company sold its remaining TRELEGY royalty interest to GSK in late 2025).

Product and service1 record
1YUPELRI® (revefenacin) Inhalation Solution
CategorySpecialty respiratory pharmaceutical - COPD maintenance therapy
Description

FDA-approved once-daily nebulized long-acting muscarinic antagonist (LAMA) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Co-commercialized with Viatris in the United States, with Viatris handling sales force, distribution, and managed markets.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

Hatch-Waxman patent litigation settlement resolving all YUPELRI-related litigation. Mankind Pharma granted royalty-free, non-exclusive US license to market generic YUPELRI starting April 23, 2039. Settlement covers three US patents (11,484,531; 12,048,692; 12,285,417) and is subject to DOJ and FTC review.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Strategic collaboration with Viatris for co-commercialization of YUPELRI (revefenacin) in the United States. Viatris and Theravance co-commercialize the product, with Viatris handling sales force, distribution, and managed markets while Theravance maintains brand leadership. This is the company's primary commercial partnership following restructuring.

Strategic tierCoreTypeOthers
Description

Investment bank advising the Strategic Review Committee in evaluating strategic alternatives including potential sale of the company.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

India-headquartered global pharmaceutical company with one of the largest respiratory product portfolios, including nebulized therapies. Comparable as an emerging global player with directly overlapping COPD/inhalation offerings.

TypeDirect peer
Description

Specialty respiratory biopharma with Ohtuvayre (ensifentrine), a first-in-class COPD maintenance therapy. Closely comparable to Theravance as a small, focused COPD-focused commercial-stage company, though Verona is now owned by Merck following the 2024 acquisition.

TypeBroad incumbent
Description

Global specialty and generics pharmaceutical company and Theravance's co-commercialization partner for YUPELRI in the US. Comparable as the dominant counterparty in YUPELRI economics and as a broad respiratory/generics incumbent.

TypeBroad incumbent
Description

Global respiratory leader with TRELEGY Ellipta — the product whose sales trigger Theravance's milestone payments. Comparable as a respiratory pharmaceutical incumbent with overlapping COPD franchise economics.

5Boehringer Ingelheim
TypeBroad incumbent
Description

Major respiratory pharmaceutical incumbent with Spiriva (tiotropium), the original LAMA that defined the COPD maintenance category YUPELRI competes in. Comparable as a broad respiratory market leader with overlapping mechanism of action.

TypeBroad incumbent
Description

Global respiratory pharmaceutical leader with Breztri/Trixeo Aerosphere, a triple-therapy COPD product directly competing with GSK's TRELEGY and adjacent to YUPELRI's market. Comparable as a broad incumbent shaping the COPD competitive set.

TypeRegional player
Description

Indian pharmaceutical company that settled Theravance's YUPELRI Hatch-Waxman litigation and holds a non-exclusive US generic license starting April 2039. Comparable as a respiratory-focused generics player with direct interest in the same molecule.

TypeEmerging player
Description

India-based specialty and generics pharmaceutical company with a meaningful respiratory franchise (inhalers, nebulized products). Comparable as an emerging global respiratory player overlapping YUPELRI's nebulized delivery space.

TypeEmerging player
Description

Clinical-stage biopharma developing inhaled therapeutics for respiratory infections and inflammation. Comparable as a small, respiratory-focused biopharma working in the same inhaled/nebulized therapeutic category.

TypeBroad incumbent
Description

Privately held global respiratory pharmaceutical company with established COPD and asthma franchises (e.g., Trimbow, Foster). Comparable as a respiratory-focused incumbent competing in the same maintenance-COPD therapeutic area.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Theravance Biopharma

Specialty Respiratory Pharmaceuticalstheravance.com

Theravance Biopharma is a public biopharmaceutical company (NASDAQ: TBPH) that co-commercializes YUPELRI, a nebulized COPD maintenance therapy, with Viatris in the United States, and receives milestone payments from Royalty Pharma tied to GSK's TRELEGY sales.

What Theravance Biopharma does

Theravance Biopharma is a publicly traded biopharmaceutical company (NASDAQ: TBPH) headquartered in South San Francisco, California, with an additional office in Dublin, Ireland. The company was established in June 2014 as a spin-off from Innoviva and focuses on specialty respiratory diseases. Its commercial portfolio consists of a single FDA-approved product, YUPELRI (revefenacin) inhalation solution, a once-daily long-acting muscarinic antagonist (LAMA) delivered via nebulization for the maintenance treatment of chronic obstructive pulmonary disease (COPD). YUPELRI is co-commercialized in the United States through a strategic partnership with Viatris, under which Viatris handles sales force deployment, distribution, and managed markets while Theravance maintains brand leadership. The company also receives milestone payments from Royalty Pharma triggered by GSK-reported TRELEGY Ellipta net sales, with a $100 million payment expected in 2026.

Theravance's revenue model is structured around three streams: YUPELRI collaboration revenue shared with Viatris, sales-based milestones tied to YUPELRI performance ($75 million achieved in FY2025), and TRELEGY milestone payments from Royalty Pharma. FY2025 YUPELRI US net sales reached $266.6 million (up 12% year-over-year), with Q1 2026 collaboration revenue of $17.7 million (up 15% year-over-year). The company holds three US patents (11,484,531; 12,048,692; 12,285,417) on YUPELRI, and a March 2026 Hatch-Waxman settlement with Mankind Pharma extended generic-free exclusivity through April 2039.

Following the March 2026 failure of the Phase 3 CYPRESS trial for ampreloxetine (a norepinephrine reuptake inhibitor for neurogenic orthostatic hypotension), Theravance eliminated its R&D function and reduced its workforce by approximately 50%, from roughly 100 to 50 employees. The restructuring targets a 60% operating expense reduction and $60-70 million in annualized cash flow beginning in Q3 2026. The company holds approximately $400 million in cash with no debt as of Q1 2026, and a Strategic Review Committee, advised by Lazard, is actively evaluating potential sale of the company as a strategic alternative.

Theravance Biopharma firmographics

Firmographics
Name
Theravance Biopharma
Legal name
Theravance Biopharma US, LLC
Website
https://theravance.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
Theravance Biopharma is a public biopharmaceutical company (NASDAQ: TBPH) that co-commercializes YUPELRI, a nebulized COPD maintenance therapy, with Viatris in the United States, and receives milestone payments from Royalty Pharma tied to GSK's TRELEGY sales.
Ownership category
akta.pro rank

Theravance Biopharma industry classification

Industry
Product category
Specialty Respiratory Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Respiratory therapeutics
  • COPD treatment
  • Inhaled pharmaceuticals
  • Nebulized LAMA therapy
  • Specialty biopharmaceuticals

Where Theravance Biopharma is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Theravance Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. YUPELRI collaboration revenue: Revenue from strategic collaboration with Viatris for co-commercialization of YUPELRI in the US. Viatris and Theravance co-commercialize the product, sharing economics.
  2. TRELEGY milestone payments: Royalty Pharma milestone payments triggered by GSK-reported TRELEGY net sales. $100 million milestone payment expected in 2026. Also received $50 million milestone payment previously.
  3. YUPELRI sales-based milestones: Additional milestone payments tied to YUPELRI sales performance. $75 million in sales-based milestones achieved in FY2025.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Theravance Biopharma product offering

Product offering

Core offering

Theravance Biopharma is a specialty biopharmaceutical company that develops and commercializes therapeutics for respiratory diseases. Its core offering is YUPELRI® (revefenacin), an FDA-approved long-acting muscarinic antagonist (LAMA) inhalation solution for maintenance treatment of COPD, co-commercialized in the US with Viatris. The company also derives revenue from royalty milestone payments tied to GSK's TRELEGY Ellipta net sales through Royalty Pharma.

Product overview

Theravance Biopharma is a biopharmaceutical company focused on respiratory, inflammatory, and rare diseases. The company's portfolio consists of one FDA-approved product (YUPELRI® for COPD) and one discontinued pipeline candidate (amprexloxetine for neurogenic orthostatic hypotension, terminated after Phase 3 failure). Following the March 2026 strategic restructuring after the ampreloxetine trial failure, the company eliminated its R&D function and is now focused solely on commercializing YUPELRI in partnership with Viatris, while receiving milestone payments from GSK's TRELEGY (though the company sold its remaining TRELEGY royalty interest to GSK in late 2025).

Differentiator

Problem solved

Functional benefit

Brands

  • YUPELRI (revefenacin): FDA-approved inhalation solution for maintenance treatment of COPD
  • Theravance Biopharma US, LLC
  • Theravance Biopharma Ireland Limited

Products and services

  • YUPELRI® (revefenacin) Inhalation Solution FDA-approved once-daily nebulized long-acting muscarinic antagonist (LAMA) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Co-commercialized with Viatris in the United States, with Viatris handling sales force, distribution, and managed markets.

Quantifiable outcome

  • YUPELRI achieved $266.6M in FY2025 US net sales, up 12% year-over-year
  • +4 more outcomes

Companies that use Theravance Biopharma

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Theravance Biopharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Theravance Biopharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Mankind PharmacoreStrategic or Co-development Partner · 1 March 2026Hatch-Waxman patent litigation settlement resolving all YUPELRI-related litigation. Mankind Pharma granted royalty-free, non-exclusive US license to market generic YUPELRI starting April 23, 2039. Settlement covers three US patents (11,484,531; 12,048,692; 12,285,417) and is subject to DOJ and FTC review.
  • ViatriscoreChannel Partner/ Reseller/ DistributorStrategic collaboration with Viatris for co-commercialization of YUPELRI (revefenacin) in the United States. Viatris and Theravance co-commercialize the product, with Viatris handling sales force, distribution, and managed markets while Theravance maintains brand leadership. This is the company's primary commercial partnership following restructuring.
  • LazardcoreOthersInvestment bank advising the Strategic Review Committee in evaluating strategic alternatives including potential sale of the company.

Scale indicators15 records

Recent moves6 records

Expansion highlights5 records

Theravance Biopharma competitors and assessment

Company assessment

Emerging players

  • Cipla: India-headquartered global pharmaceutical company with one of the largest respiratory product portfolios, including nebulized therapies. Comparable as an emerging global player with directly overlapping COPD/inhalation offerings.
  • Lupin Pharmaceuticals: India-based specialty and generics pharmaceutical company with a meaningful respiratory franchise (inhalers, nebulized products). Comparable as an emerging global respiratory player overlapping YUPELRI's nebulized delivery space.
  • Inhalon Biopharma: Clinical-stage biopharma developing inhaled therapeutics for respiratory infections and inflammation. Comparable as a small, respiratory-focused biopharma working in the same inhaled/nebulized therapeutic category.

Direct peers

  • Verona Pharma: Specialty respiratory biopharma with Ohtuvayre (ensifentrine), a first-in-class COPD maintenance therapy. Closely comparable to Theravance as a small, focused COPD-focused commercial-stage company, though Verona is now owned by Merck following the 2024 acquisition.

Broad incumbents

  • Viatris: Global specialty and generics pharmaceutical company and Theravance's co-commercialization partner for YUPELRI in the US. Comparable as the dominant counterparty in YUPELRI economics and as a broad respiratory/generics incumbent.
  • GSK (GlaxoSmithKline): Global respiratory leader with TRELEGY Ellipta — the product whose sales trigger Theravance's milestone payments. Comparable as a respiratory pharmaceutical incumbent with overlapping COPD franchise economics.
  • Boehringer Ingelheim: Major respiratory pharmaceutical incumbent with Spiriva (tiotropium), the original LAMA that defined the COPD maintenance category YUPELRI competes in. Comparable as a broad respiratory market leader with overlapping mechanism of action.
  • AstraZeneca: Global respiratory pharmaceutical leader with Breztri/Trixeo Aerosphere, a triple-therapy COPD product directly competing with GSK's TRELEGY and adjacent to YUPELRI's market. Comparable as a broad incumbent shaping the COPD competitive set.
  • Chiesi Farmaceutici: Privately held global respiratory pharmaceutical company with established COPD and asthma franchises (e.g., Trimbow, Foster). Comparable as a respiratory-focused incumbent competing in the same maintenance-COPD therapeutic area.

Regional players

  • Mankind Pharma: Indian pharmaceutical company that settled Theravance's YUPELRI Hatch-Waxman litigation and holds a non-exclusive US generic license starting April 2039. Comparable as a respiratory-focused generics player with direct interest in the same molecule.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Theravance Biopharma social profiles

Digital presence

Theravance Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Theravance Biopharma leadership team

Management profile

Number of profiles

Profiles7 records

Theravance Biopharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Theravance Biopharma funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Theravance Biopharma M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Theravance Biopharma

What does Theravance Biopharma do?

Theravance Biopharma is a specialty biopharmaceutical company that develops and commercializes therapeutics for respiratory diseases. Its core offering is YUPELRI® (revefenacin), an FDA-approved long-acting muscarinic antagonist (LAMA) inhalation solution for maintenance treatment of COPD, co-commercialized in the US with Viatris. The company also derives revenue from royalty milestone payments tied to GSK's TRELEGY Ellipta net sales through Royalty Pharma.

Is Theravance Biopharma a public or private company?

Theravance Biopharma is a public company. It is classified as public and is currently operating.

When was Theravance Biopharma founded?

Theravance Biopharma was founded in 2014. It employs 101 to 250 people.

Where is Theravance Biopharma based?

Theravance Biopharma is headquartered in South San Francisco, United States, in the North America region.

How does Theravance Biopharma make money?

Three revenue lines are on record. YUPELRI collaboration revenue is the primary driver. The others are TRELEGY milestone payments and YUPELRI sales-based milestones.

Who are Theravance Biopharma's main competitors?

Emerging players on record are Cipla, Lupin Pharmaceuticals and Inhalon Biopharma. Verona Pharma is listed as a direct peer. Broad incumbents are Viatris, GSK (GlaxoSmithKline), Boehringer Ingelheim, AstraZeneca and Chiesi Farmaceutici. Mankind Pharma is listed as a regional player.

Does Theravance Biopharma have an API?

No public API is recorded for Theravance Biopharma.

What industry is Theravance Biopharma in?

Theravance Biopharma's product category is Specialty Respiratory Pharmaceuticals. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsZymeworks (NASDAQ: ZYME) swings to a profit on a $250 million Jazz milestoneZymeworks reported a third-quarter net income of $173.7 million, up from a $19.6 million loss, driven by a $250 million Jazz milestone for Ziihera. Revenue rose to $256.5 million, and the company raised its 2026 revenue guidance to $337–$351 million. It also closed its Theravance Biopharma acquisition.GlobeNewswireZymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsZymeworks reported Q3 2026 revenue of $256.5 million, up from $27.6 million, driven by a $250 million milestone from Jazz for Ziihera's U.S. approval. The company raised its 2026 revenue guidance to $337–351 million and adjusted EBITDA to $176–190 million. It also completed the Theravance Biopharma acquisition and announced a Roche collaboration for ZW209.Business & FinancialZymeworks Provides Corporate Update And Reports Third Quarter 2026 Financial ResultsZymeworks reported Q3 2026 revenue of $256.5 million, up from $27.6 million, driven by a $250 million milestone from Jazz for Ziihera's U.S. approval. The company raised its 2026 revenue guidance to $337–351 million and adjusted EBITDA to $176–190 million. It also completed the Theravance Biopharma acquisition and announced a Roche collaboration for ZW209.American Banking and Market NewsAnalyzing Theravance Biopharma (NASDAQ:TBPH) & Palisade Bio (NASDAQ:PALI)Palisade Bio beats Theravance Biopharma on 8 of 15 factors, including analyst ratings and valuation. Palisade has a consensus target price of $9.29 (673.81% upside) versus Theravance's $19.40 (13.92% upside). Palisade's beta is 1.61, while Theravance's is 0.25.Ticker ReportContrasting Theravance Biopharma (NASDAQ:TBPH) & Gyre Therapeutics (NASDAQ:GYRE)Theravance Biopharma and Gyre Therapeutics are compared on institutional ownership, analyst ratings, and financials. Theravance has 99.1% institutional ownership and a consensus price target of $19.40, while Gyre has 24% institutional ownership and a lower P/E ratio. Theravance beats Gyre on 10 of 13 factors.Ticker ReportLipocine (NASDAQ:LPCN) vs. Theravance Biopharma (NASDAQ:TBPH) Head to Head ReviewTheravance Biopharma and Lipocine are compared on profitability, valuation, and analyst ratings. Theravance has higher revenue and earnings, but Lipocine shows a larger upside potential. Analysts rate Lipocine more favorably due to its higher probable upside.American Banking and Market NewsTheravance Biopharma, Inc. (NASDAQ:TBPH) Stock Rated “Hold” by Wall Street BrokeragesTheravance Biopharma received a consensus 'Hold' rating from eight analysts, with an average price objective of $19.40. The company reported Q2 EPS of -$0.11, missing the $0.07 consensus, and revenue of $20.73 million versus $22.49 million estimated. Analysts forecast 1.56 EPS for the current fiscal year.citybizZymeworks Appoints Suzanne Monahan Senior Vice President and General Manager of Theravance BiopharmaZymeworks appointed Suzanne Monahan senior vice president and general manager of Theravance Biopharma, effective October 19, 2026. She will oversee commercial strategy for YUPELRI, a COPD treatment, and report to CEO Kenneth Galbraith. The appointment supports Zymeworks' expansion of commercial operations following the Theravance acquisition.Investing.comZymeworks appoints Suzanne Monahan as commercial headZymeworks appointed Suzanne Monahan as Senior Vice President, Commercial and General Manager of Theravance Biopharma, effective immediately. She will lead commercial strategy for YUPELRI, a nebulized drug for COPD, following the company's acquisition of Theravance Biopharma. Monahan brings over 20 years of commercial leadership experience.The future of tradingZymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance BiopharmaZymeworks appointed Suzanne Monahan as Senior Vice President, Commercial and General Manager of Theravance Biopharma, effective immediately. She will lead commercial strategy for YUPELRI, the first once-daily nebulized LAMA for COPD, following the company's acquisition of Theravance Biopharma.